BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Eurobiomed - ECPv6.10.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eurobiomed
X-ORIGINAL-URL:https://www.eurobiomed.org
X-WR-CALDESC:Évènements pour Eurobiomed
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241210T090000
DTEND;TZID=Europe/Paris:20241210T170000
DTSTAMP:20260404T220210
CREATED:20241030T092039Z
LAST-MODIFIED:20250110T140904Z
UID:20431-1733821200-1733850000@www.eurobiomed.org
SUMMARY:3rd edition of Immunology Days
DESCRIPTION:Eurobiomed is pleased to invite you to the 3rd edition of Immunology Days\, to be held at the EMD in Marseille. Under the theme “ All committed to the development of immune therapies against cancer\, inflammatory and infectious diseases ”\, this year’s event will bring together key players from research and industry to advance innovations in immunology. This unique event offers a space dedicated to exchanging knowledge and sharing scientific advances in the field of immunology. Participants will be able to attend presentations of innovative projects and discover new perspectives on immune therapies\, all in a setting conducive to scientific interaction. \n			\n			\n				\n				\n				\n				\n			\n				\n				\n				\n				\n				\n				\n				\n				\n				\n				\n				PROGRAM\n			\n				\n				\n				\n				\n				\n				\n				\n					\n			\n				\n			\n		   \n				09:00\n				   		\n					09:00\n					\n					\n					\n						Welcome - Coffee\n						\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				09:30\n				   		\n					09:30\n					\n					\n					\n						Introduction\n						 \nEmilie ROYERE - Directrice Générale\, Eurobiomed\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				09:50\n				   		\n					09:50\n					\n					\n					\n						Words from local authorities\n						 \nMme Emmanuelle CHARAFE - Vice-présidente de la Métropole déléguée à la Santé\, à l’Enseignement supérieur et la Recherche\, à la Recherche médicale\, à l’économie de la santé. \n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				10:00\n				   		\n					10:00\n					\n					\n					\n						An update : MIB\, an International Biocluster in Immunology \n						 \nPr Daniel OLIVE - MD PhD\, Aix-Marseille Université\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n		\n		\n				\n			\n				\n				\n				\n				\n				Part 1: Ambition to accelerate\, target discovery\, validation and success \n			\n				\n				\n				\n				\n				\n				\n				\n					\n			\n				\n			\n		   \n				10:20\n				   		\n					10:20\n					\n					\n					\n						Validating the Functional Characteristics of Live  Immune Cells at a Single-Cell Level through Beacon\,\n						 \nM. Tiago SANTOS - Market Development Executive\, Bruker Cellular Analysis\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				10:50\n				   		\n					10:50\n					\n					\n					\n						Harnessing the potential of CAR-T cell therapy through new cellular engineering and models\n						 \nPr. Bernard MALISSEN – Directeur Emérite de Recherche CNRS\, Ancien Directeur du CIML\, Ancien Directeur et Fondateur du CIPHE\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				11:20\n				   		\n					11:20\n					\n					\n					\n						C2IT\, When IPC and APHM join forces to reinforce clinical trials in immunology\n						 \nPr Norbert VEY - Managing Director\, Institut Paoli-Calmettes & Emilie GARRIDO PRADALIE - Directrice Recherche en Santé et Maladies Rares\, Assistance Publique - Hôpitaux de Marseille\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				11:50\n				   		\n					11:50\n					\n					\n					\n						Challenges and opportunities for the development of prospective cohorts in autoimmune diseases: a case study in lupus and vasculitis\,\n						 \nPr. Noémie Jourde-Chiche - MD\, PhD - Aix-Marseille Université\, Assistance Publique - Hôpitaux de Marseille - Hôpital de la Conception\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n		\n		\n				\n			\n				\n				\n				\n				\n				12h20 : Lunch and Networking \n			\n				\n				\n				\n				\n				\n				\n				\n					\n			\n				\n			\n		   \n				13 : 45\n				   		\n					13 : 45\n					\n					\n					\n						Key Note : Sanofi\, a global strategy to target immune-diseases\,\n						 \nMr. Frédéric MARRACHE - VP -Global Project Head - Clinical Development - Immunology and Inflammation Therapeutic Area\, SANOFI\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n		\n		\n				\n			\n				\n				\n				\n				\n				Part 2: A hub for industrial innovation from discovery to industrialization \n			\n				\n				\n				\n				\n				\n				\n				\n					\n			\n				\n			\n		   \n				14:15\n				   		\n					14:15\n					\n					\n					\n						Remora Biotech Venture Builder : new generation of first-in class and multifunctional immunotherapy products to treat cancer and AID\n						 \n Mr. David BECHARD- PhD CEO\,  Remora Biotech France – Nanomunity – Radiomune Pharma\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				14:45\n				   		\n					14:45\n					\n					\n					\n						Antibody discovery and repertoire analysis using single cell Beacon technology\,\n						 \nPr. François ROMAGNE - Scientific Director\, MImAbs\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				15:15\n				   		\n					15:15\n					\n					\n					\n						ICT01 in combination with venetoclax & azacitidine : from preclinical PoC to Phase 1 interim results\, \n						 \nAude DE GASSART\, VP Preclinical Development - Imcheck Therapeutics \n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				15:45\n				   		\n					15:45\n					\n					\n					\n						New opportunities for democratizing the use of flow cytometry\n						 \n Mr. Fabrice MALERGUE- PhD Senior Staff Research Scientist\, Beckman Coulter Life Sciences/ Immunotech\n\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				16:15\n				   		\n					16:15\n					\n					\n					\n						Networking \n						\n						\n						\n						\n				\n				\n					\n					\n				\n			\n				17:00\n				   		\n					17:00\n					\n					\n					\n						End \n						\n						\n						\n						\n				\n				\n					\n					\n				\n			\n		\n		\n				\n			\n				\n				\n				\n				\n				About MIB \nLocated at the center of Marseille\, home of immunology research for over 40 years\, the mission of MIB is to develop and implement cooperation between all stakeholders of tomorrow’s immunology at the national and international levels. Researchers\, hospital practitioners\, biotechs & pharma innovators\, investors\, students and public authorities will benefit from a dynamic environment (technology platforms\, immunology start-up studios\, support for SMEs and larger companies\, etc.) and complementary expertise to develop cutting-edge immune-based therapies and new diagnostic tools. With a budget of €97 million as part of the France 2030 Plan\, MIB aims to accelerate translational research in immunology\, focusing on four therapeutic areas: oncology\, infectiology\, autoimmune and inflammatory diseases\, for the benefit of patients. \nMIB partners : \n			\n				\n				\n				\n				\n				\n			\n				\n				\n				\n				\n				\n			\n				\n				\n				\n				\n				During this event you will have a table for the dispositif Move2Digital
URL:https://www.eurobiomed.org/evenement/3rd-edition-of-immunology-days/
LOCATION:EMD Business School\, Rue Joseph Biaggi\, Marseille\, 13003\, France
CATEGORIES:Rencontre thématique
ATTACH;FMTTYPE=image/png:https://www.eurobiomed.org/wp-content/uploads/2024/10/post-n°3-LinkedIn-.png
END:VEVENT
END:VCALENDAR